Published

Psilocin, the Psychoactive Metabolite of Psilocybin, Modulates Select Neuroimmune Functions of Microglial Cells in a 5-HT2 Receptor-Dependent Manner

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: Molecules
Date: 2024-10-28
Source: Crossref
DOI: 10.3390/molecules29215084
PubMed: 39519725

Authors

Wiens Kennedy R.Brooks Noah A. H.Riar Ishvin Greuel Bridget K.Lindhout Ivan A.Klegeris Andis

Watch author

Derived topics and classifications

psilocybin psilocin Receptor Pharmacology Oxidative Stress Inflammation Immune Function Other

Citation graph

40 referenced DOIs found in stored source metadata. 4 indexed papers cite this DOI.

Open citation network

10.1038/s41593-020-0687-6 10.1016/s1474-4422(15)70016-5 10.1186/s13024-019-0333-5 10.3390/cells9071717 10.1111/jnc.15327 10.1155/2021/7086512 10.3389/fnins.2021.742065 10.1016/j.clinbiochem.2019.04.001 10.3389/fnagi.2018.00083 10.1007/bf03325217 10.3233/jad-141506 10.3390/antiox9080669

Indexed papers citing this DOI

Psilocybin restores behavior and 5-HT2A signaling while reducing microglial density after chronic traumatic brain injury in rats2026-07-01 DESI-MSI-Based Multi-Organ Distribution Mapping of Psilocin in Zebrafish2026-06-18 Psilocin alleviates acute itch in mice: possible involvement of 5-HT2A receptors and kynurenine pathway2025-10-01 Psilocin, the Psychoactive Metabolite of Psilocybin, Modulates Select Neuroimmune Functions of Microglial Cells in a 5-HT2 Receptor-Dependent Manner2024-10-28

Related papers

Strategic Neurodelivery of Psychedelic Compounds: Bridging Molecular Pharmacology with Therapeutic Innovation in CNS Disorders.CNS & neurological disorders drug targets · 2026-03-11 Psilocybin in Alcohol Use Disorder With Comorbid DepressionClinicalTrials.gov · 2025-03-19 Investigating the Therapeutic Effects of Psilocybin in Treatment-Resistant Post-Traumatic Stress DisorderClinicalTrials.gov · 2023-06-29 Safety and Efficacy of Psilocybin for Body Dysmorphic DisorderClinicalTrials.gov · 2023-03-13 Psychedelics in the treatment of unipolar and bipolar depression.International journal of bipolar disorders · 2022-07-05 Feasibility Phase 2 Study of Psilocybin-Assisted Therapy for Opioid-Refractory Pain in Patients With Advanced CancerClinicalTrials.gov · 2026-08-05 CAPSI - Cancer Related Major Depression Treated With a Single Dose of Psilocybin: A Multicenter Randomized Placebo Controlled Double Blind Clinical TrialClinicalTrials.gov · 2026-04-13 The Effect of Psilocybin on MDD Symptom Severity and Synaptic Density - A Single Dose Randomized, Double Blind, Placebo- Controlled Phase 2 Positron Emission Tomography StudyClinicalTrials.gov · 2024-04-19